Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Agne Paner

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Blood Reviews|December 11, 2019
The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myelomaAgne Paner, Pritesh Patel, Binod Dhakal
International Journal of Nephrology|September 27, 2018
Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple MyelomaBenjamin A Derman, Jochen Reiser, Sanjib Basu, et al.
Expert Review of Hematology|October 20, 2018
Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicitiesAgne Paner, Tochukwu M Okwuosa, Kristin J Richardson, et al.
European Journal of Case Reports in Internal Medicine|March 27, 2023
NEW-ONSET CARDIAC AMYLOIDOSIS WHILE IN REMISSION FROM SYSTEMIC AL AMYLOIDOSISAbiodun Idowu, Lillian Tung, Catherine Chu, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|June 30, 2018
Light Chain Amyloidosis Presenting as Bilateral External Auditory Canal Obstructing MassesShenon Sethi, Agne Paner, Tochukwu Okwuosa, et al.
Frontiers in Oncology|October 2, 2025
A discrete choice experiment analysis to understand patient preferences for multiple myeloma treatmentsBeth Faiman, Hoa H Le, Julie Laurent, et al.
Drugs of Today (Barcelona, Spain : 1998)|August 19, 2022
Melphalan flufenamide for relapsed/refractory multiple myelomaOmar Nadeem, Maria-Victoria Mateos, Yvonne A Efebera, et al.
Cardiovascular Endocrinology & Metabolism|June 11, 2021
Exercise, cancer and cardiovascular disease: what should clinicians advise?Allison Zimmerman, Maria Isabel Camara Planek, Catherine Chu, et al.
Expert Opinion on Investigational Drugs|September 14, 2020
Melflufen for relapsed and refractory multiple myelomaAlbert Oriol, Alessandra Larocca, Xavier Leleu, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2026
Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment SelectionSamer Al Hadidi, Caitlin Costello, Luciano J Costa, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Blood Reviews|December 11, 2019
The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myelomaAgne Paner, Pritesh Patel, Binod Dhakal
International Journal of Nephrology|September 27, 2018
Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple MyelomaBenjamin A Derman, Jochen Reiser, Sanjib Basu, et al.
Expert Review of Hematology|October 20, 2018
Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicitiesAgne Paner, Tochukwu M Okwuosa, Kristin J Richardson, et al.
European Journal of Case Reports in Internal Medicine|March 27, 2023
NEW-ONSET CARDIAC AMYLOIDOSIS WHILE IN REMISSION FROM SYSTEMIC AL AMYLOIDOSISAbiodun Idowu, Lillian Tung, Catherine Chu, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|June 30, 2018
Light Chain Amyloidosis Presenting as Bilateral External Auditory Canal Obstructing MassesShenon Sethi, Agne Paner, Tochukwu Okwuosa, et al.
Frontiers in Oncology|October 2, 2025
A discrete choice experiment analysis to understand patient preferences for multiple myeloma treatmentsBeth Faiman, Hoa H Le, Julie Laurent, et al.
Drugs of Today (Barcelona, Spain : 1998)|August 19, 2022
Melphalan flufenamide for relapsed/refractory multiple myelomaOmar Nadeem, Maria-Victoria Mateos, Yvonne A Efebera, et al.
Cardiovascular Endocrinology & Metabolism|June 11, 2021
Exercise, cancer and cardiovascular disease: what should clinicians advise?Allison Zimmerman, Maria Isabel Camara Planek, Catherine Chu, et al.
Expert Opinion on Investigational Drugs|September 14, 2020
Melflufen for relapsed and refractory multiple myelomaAlbert Oriol, Alessandra Larocca, Xavier Leleu, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2026
Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment SelectionSamer Al Hadidi, Caitlin Costello, Luciano J Costa, et al.
Pageof 3